Caspofungin: a new therapeutic option for fungal endocarditis

Nevado, Jaime; Alarcón, Arı́stides de; Hernández, Antonio F.

doi:10.1111/j.1469-0691.2005.01078.x

Cited by 17 publications

(11 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the first of the echinocandins to be approved for the treatment of IC, caspofungin has been used extensively for the treatment of all forms of serious candidal infections over the past 4 years (87,114,134,171,261). Thus far, clinical experience with caspofungin and IC has been good (41,87,114,163,171).…”

Section: Trends In Antifungal Susceptibility In Relation To Time Geomentioning

confidence: 99%

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem

2007

View full text Add to dashboard Cite

SUMMARY Invasive candidiasis (IC) is a leading cause of mycosis-associated mortality in the United States. We examined data from the National Center for Health Statistics and reviewed recent literature in order to update the epidemiology of IC. IC-associated mortality has remained stable, at approximately 0.4 deaths per 100,000 population, since 1997, while mortality associated with invasive aspergillosis has continued to decline. Candida albicans remains the predominant cause of IC, accounting for over half of all cases, but Candida glabrata has emerged as the second most common cause of IC in the United States, and several less common Candida species may be emerging, some of which can exhibit resistance to triazoles and/or amphotericin B. Crude and attributable rates of mortality due to IC remain unacceptably high and unchanged for the past 2 decades. Nonpharmacologic preventive strategies should be emphasized, including hand hygiene; appropriate use, placement, and care of central venous catheters; and prudent use of antimicrobial therapy. Given that delays in appropriate antifungal therapy are associated with increased mortality, improved use of early empirical, preemptive, and prophylactic therapies should also help reduce IC-associated mortality. Several studies have now identified important variables that can be used to predict risk of IC and to help guide preventive strategies such as antifungal prophylaxis and early empirical therapy. However, improved non-culture-based diagnostics are needed to expand the potential for preemptive (or early directed) therapy. Further research to improve diagnostic, preventive, and therapeutic strategies is necessary to reduce the considerable morbidity and mortality associated with IC.

show abstract

Section: Trends In Antifungal Susceptibility In Relation To Time Geomentioning

confidence: 99%

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem

2007

View full text Add to dashboard Cite

show abstract

“…has led to extensive use of this agent for the treatment of all forms of serious candidal infections over the past 4 years (9,12,17,25). Thus far, clinical experience with caspofungin and invasive candidiasis has been good (9,14,17). However, recent reports describing the emergence of caspofungin resistance during treatment of esophagitis (6) and endocarditis (15) raise concerns about the potential emergence of caspofungin-resistant Candida species.…”

mentioning

confidence: 97%

“…The potent, broad-spectrum fungicidal activity of caspofungin against Candida spp. has led to extensive use of this agent for the treatment of all forms of serious candidal infections over the past 4 years (9,12,17,25). Thus far, clinical experience with caspofungin and invasive candidiasis has been good (9,14,17).…”

mentioning

confidence: 99%

“…Caspofungin is the first of three new echinocandin antifungal agents to become available for the treatment of invasive mycoses (3,7,11,17,19,21,22,26,28). Like other echinocandins, caspofungin acts via inhibition of 1,3-␤-D-glucan synthase, an enzyme necessary for the formation of the essential cell wall component of Candida and other important fungal pathogens (3).…”

mentioning

confidence: 99%

See 1 more Smart Citation

In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance

Pfaller¹,

Boyken²,

Hollis³

et al. 2006

J Clin Microbiol

176

130

View full text Add to dashboard Cite

Of the 25 isolates with caspofungin MICs of >1 g/ml, 12 isolates were C. parapsilosis, 6 isolates were C. guilliermondii, 2 isolates were C. rugosa, and 1 isolate each was C. albicans, C. glabrata, C. krusei, C. lusitaniae, and C. tropicalis. There was no significant change in caspofungin activity over the 4-year study period. Likewise, there was no difference in activity by geographic region. Caspofungin has excellent in vitro activity against invasive clinical isolates of Candida from centers worldwide. Our prospective sentinel surveillance reveals no evidence of emerging caspofungin resistance among invasive clinical isolates of Candida.

show abstract

“…However, in recent reports, resistance to caspofungin has been reported in Candida species during treatment with esophagitis and endocarditis. Echinocandin resistance in Candida species is caused by a specific mutation in FKS1 gene (encoding the necessary components for the synthesis of complex glucan) (33)(34)(35). Due to resistance to caspofungin, design of peptides can be an effective alternative to the treatment of vulvovaginitis caused by C. albicans.…”

mentioning

confidence: 99%

Investigation of the Inhibitory Effects of the Designed NK95 Peptide on Expression of SAP4-SAP6 Genes of Candida albicans in Comparison with Caspofungin

Keikha

Yadegari

Rajabibazl

et al. 2017

Iran Red Crescent Med J

View full text Add to dashboard Cite

Background: Candida albicans is the most common pathogen in patients with vulvovaginitis. Secretory aspartyl proteinases (SAPs) are potential factors in the virulence of C. albicans. Antimicrobial peptides (AMPs) are recognized as a promising antimicrobial group of drugs with a membrane degradation mechanism. Occurrence of resistance to these drugs is quite rare. The impact of rapid membrane degradation on AMPs is relative to the prevention or delay in drug resistance mechanisms in different microbes. Objectives: The purpose of this study was to compare the inhibitory effects of the designed NK95 peptide and caspofungin on expression of SAP4-SAP6 genes from clinical vaginal isolates of C. albicans . Methods: In this experimental study, samples were collected from 350 women, who were suspected of vulvovaginal candidiasis and were referred to Zahedan gynecology clinics during 6 months. The clinical specimens were cultured in Sabouraud glucose agar (SGA). Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used to identify the vaginal isolates of C. albicans. Afterwards, the NK95 peptide was designed and synthesized. Drug susceptibility test was carried out at different concentrations of NK95 peptide and caspofungin. RNA extraction, cDNA synthesis, and quantitative Real-time PCR were performed on the clinical isolates before and after treatment with the designed peptide and caspofungin. Results: Based on the findings of this study, the minimum inhibitory concentration (MIC90), MIC50, and minimum fungicidal con-

show abstract

Caspofungin: a new therapeutic option for fungal endocarditis

Cited by 17 publications

References 5 publications

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem

In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance

Investigation of the Inhibitory Effects of the Designed NK95 Peptide on Expression of SAP4-SAP6 Genes of Candida albicans in Comparison with Caspofungin

Contact Info

Product

Resources

About